VACCINEX, INC.
VCNX evidence brief
What we can confirm
- Market Cap:
- $2.8M
What it means
What to watch
Prepared research question
What matters most for VCNX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VCNX
Vaccinex, Inc. (VCNX) is a clinical-stage biotechnology company developing therapies for Alzheimer's disease and cancer by inhibiting semaphorin 4D (SEMA4D), with its lead candidate pepinemab in Phase 2 trials.
Key risk: Low cash runway
Market Cap
$2.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2024.
Tracking 1 clinical trial for VACCINEX, INC..
Vaccinex, Inc. (VCNX) is a clinical-stage biotechnology company developing therapies for Alzheimer's disease and cancer by inhibiting semaphorin 4D (SEMA4D), with its lead candidate pepinemab in Phase 2 trials.
- Lead candidate pepinemab is a monoclonal antibody targeting SEMA4D, in Phase 2 for Huntington's disease and a Phase 2b for Alzheimer's disease [pipeline][news·published 2025-12-23].
- Pepinemab has Orphan Drug and Fast Track regulatory status for Huntington's disease [pipeline].
- The company entered a $60 million revenue sharing agreement in December 2025 to fund a Phase 2b Alzheimer's trial [news·published 2025-12-23].
- Cash and equivalents were $1.1M as of 2024-12-31, with no debt [sec].
- Pipeline includes an anti-CCR8 antibody (chs-114) licensed to Coherus and a preclinical anti-CXCL13 antibody (vx5) for autoimmune disorders [pipeline].
What works
- Pepinemab has Orphan Drug and Fast Track designations from the FDA for Huntington's disease, which may accelerate development and provide market exclusivity [pipeline].
- The $60 million revenue sharing agreement secured in December 2025 provides non-dilutive funding for a Phase 2b Alzheimer's trial, reducing near-term dilution risk [news·published 2025-12-23].
- The company has multiple platform technologies (SEMA4D antibody platform and ActivMAb®) that can generate additional pipeline candidates [sec·filed 2024-05-08].
What to weigh
- Cash position is very low at $1.1M as of 2024-12-31, which may require additional financing or partnerships to sustain operations beyond the near term [sec].
- Pepinemab faces a competitive landscape with over 50 competitors in Huntington's disease, including gene therapy and small molecule approaches [pipeline].
- The company's most advanced candidate (pepinemab) is still in Phase 2, with no approved products generating revenue, creating a high dependency on clinical trial success [pipeline][news·published 2025-12-23].
From the filings
Quoted directly from source documents.
Vaccinex entered a $60 million revenue sharing agreement to fund a Phase 2b Alzheimer's trial.
“Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease”
News · December 23, 2025
The company's platforms include SEMA4D antibody and ActivMAb®.
“Our lead platform technologies include our SEMA4D antibody platform and our ActivMAb ® antibody discovery platform.”
SEC filings · May 8, 2024
Catalyst timeline
- 2022-12-10 · Phase 2 start for pepinemab in metastatic pancreatic adenocarcinoma — A Phase 1b/2 trial of immunotherapy with avelumab and pepinemab as second-line treatment for metastatic pancreatic adenocarcinoma began.
Risks & what to watch (4)›
Key risks
- Low cash runway — Cash of $1.1M as of 2024-12-31 may be insufficient to fund operations without additional financing [sec].
- No approved products — Company has no marketed products; all revenue depends on future clinical and regulatory success [pipeline].
- Competitive landscape — Pepinemab faces over 50 competitors in Huntington's disease and 215 in cancer immunotherapy [pipeline].
- Dependence on single candidate — Pepinemab is the lead candidate; pipeline diversification is limited with other assets in early/preclinical stages [pipeline].
What to watch
- Initiation and enrollment of the Phase 2b Alzheimer's trial funded by the $60M agreement [news·published 2025-12-23].
- Presentation of neoadjuvant pepinemab data in head and neck cancer at ASCO 2025 [news·published 2025-05-27].
- Any new financing or partnership announcements given the low cash position [sec].
- Progress of the Phase 2 Huntington's disease trial and potential regulatory milestones [pipeline].
Sources: Catalysts · News · Pipeline · SEC filings · Generated October 10, 2026 · How we verify sources →
Run VACCINEX, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available VACCINEX, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Dec 2024Institutional holders
1
Total value held
$45
| Holder | Shares | Value |
|---|---|---|
| barclays plc | 46 | $45 |
Short Interest
as of Apr 22, 2026- % of float
- 3.2%
- Days to cover
- 0.6
- Shares short
- 62,111
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VCNX short interestGovernance
Frequently asked questions
What is the AI investment thesis for VACCINEX, INC.?
Vaccinex, Inc. (VCNX) is a clinical-stage biotechnology company developing therapies for Alzheimer's disease and cancer by inhibiting semaphorin 4D (SEMA4D), with its lead candidate pepinemab in Phase 2 trials.
Who is the CEO of VACCINEX, INC.?
Dr. Maurice Zauderer Ph.D. is the chief executive officer of VACCINEX, INC. (VCNX).
Where is VACCINEX, INC. headquartered?
VACCINEX, INC. (VCNX) is headquartered in Rochester, NY, United States.
What therapeutic areas does VACCINEX, INC. focus on?
VACCINEX, INC. develops therapies across Oncology, Rare Disease, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.